Clinical case of psoriasis in an HIV-positive patient

Abstract

Modern ideas about psoriasis are becoming wider, while the incidence of this dermatosis is increasing every year. Psoriasis does not seem to be just a skin pathological process, since the basis of this disease is the development of chronic systemic immune inflammation resulting from the launch of a complex cascade of immune reactions with impaired activity of T-lymphocytes and the production of various pro-inflammatory cytokines and chemokines.

The course of psoriatic disease has its own characteristics in a patient with human immunodeficiency virus. The peculiarities of the course of psoriasis in a patient with human immunodeficiency virus require a personalized approach in therapy.

This article describes a clinical case of psoriasis in a patient with newly diagnosed human immunodeficiency virus. The stages of the diagnostic search for HIV infection are described. To confirm the diagnosis of psoriasis, a pathohistological examination of a skin biopsy was performed, as well as additional laboratory and instrumental studies. The main features of the course of psoriatic disease in an HIV-positive patient are demonstrated: a combination of several clinical forms of the disease, severe severity, lack of necessary positive dynamics against the background of external and basic anti-inflammatory forms of therapy.

Keywords

psoriasis / HIV-infection / case report

References

[1] Kubanov АА, Bogdanova EV. Epidemiology of psoriasis among the elderly population and volume of specialized medical care provided to patients with psoriasis in the Russian Federation in 2010–2019. Vestnik Dermatologii i Venerologii. 2020;96(5):7–18. (In Russ). doi: 10.25208/vdv1171-2020-96-5-07-18

[2] Кубанов А.А., Богданова Е.В. Эпидемиология псориаза среди населения старше трудоспособного возраста и объемы оказываемой специализированной медицинской помощи больным псориазом в Российской Федерации в 2010–2019 гг. // Вестник дерматологии и венерологии. 2020. Т. 96, № 5, С. 7–18. doi: 10.25208/vdv1171-2020-96-5-07-18

[3] Potekaev NN, Zhukova OV, Artemyeva SI. Psoriasis: A personalized approach to therapy. The preferred choice of systemic agents considering comorbid pathologies. Meditsinskiy sovet. 2020;(12):28–34. (In Russ). doi: 10.21518/2079-701X-2020-12-28-34

[4] Потекаев Н.Н., Жукова О.В., Артемьева С.И. Псориаз: персонифицированный подход к терапии. Предпочтительный выбор системных агентов с учетом коморбидных патологий // Медицинский совет. 2020. № 12. С. 28–34. doi: 10.21518/2079-701X-2020-12-28-34

[5] Lynch M, Ahern T, Sweeney CM, et al. Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction. Int J Dermatol. 2017;56(11):1103–1118. doi: 10.1111/ijd.13699

[6] Lynch M., Ahern T., Sweeney C.M., et al. Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction // Int J Dermatol. 2017. Vol. 56, N 11. P. 1103–1118. doi: 10.1111/ijd.13699

[7] Alpalhão M, Borges-Costa J, Filipe P. Psoriasis in HIV infection: An update. Int J STD AIDS. 2019;30(6):596–604. doi: 10.1177/0956462419827673

[8] Alpalhão M., Borges-Costa J., Filipe P. Psoriasis in HIV infection: An update // Int J STD AIDS. 2019. Vol. 30, N 6. P. 596–604. doi: 10.1177/0956462419827673

[9] Gong J, Weiwei W, Liguo Q, et al. Interleukin-17A inhibitor secukinumab treatment in HIV-POSITIVE psoriasis patient: A case report. Clin Cosmetic Investigational Dermatol. 2022;2949–2956. doi: 10.2147/CCID.S395348

[10] Gong J., Weiwei W., Liguo Q., et al. Interleukin-17A inhibitor secukinumab treatment in HIV-positive psoriasis patient: A case report // Clin Cosmetic Investigational Dermatol. 2022. P. 2949–2956. doi: 10.2147/CCID.S395348

[11] Ceccarelli M, Rullo VE, Vaccaro M, et al. HIV-associated psoriasis: Epidemiology, pathogenesis, and management. Dermatologic Therapy. 2019;32(2):e12806. doi: 10.1111/dth.12806

[12] Ceccarelli M., Rullo V.E., Vaccaro M., et al. HIV-associated psoriasis: Epidemiology, pathogenesis, and management // Dermatologic Therapy. 2019. Vol. 32, N 2. P. e12806. doi: 10.1111/dth.12806

[13] Chaiyabutr C, Jiamton S, Silpa-Archa N, et al. Retrospective study of psoriasis in people living with HIV: Thailand’s experience. J Dermatol. 2022;49(6):607–614. doi: 10.1111/1346-8138.16352

[14] Chaiyabutr C., Jiamton S., Silpa-Archa N., et al. Retrospective study of psoriasis in people living with HIV: Thailand’s experience // J Dermatol. 2022. Vol. 49, N 6. P. 607–614. doi: 10.1111/1346-8138.16352

[15] Morar N, Willis-Owen SA, Maurer T, et al. HIV-associated psoriasis: Pathogenesis, clinical features, and management. Lancet Inf Dis. 2010;10(7):470–478. doi: 10.1016/S1473-3099(10)70101-8

[16] Morar N., Willis-Owen S.A., Maurer T., et al. HIV-associated psoriasis: Pathogenesis, clinical features, and management // Lancet Inf Dis. 2010. Vol. 10, N 7. P. 470–478. doi: 10.1016/S1473-3099(10)70101-8

[17] Arbune M, Arbune MM, Niculetet E, et al. Therapeutic challenges of psoriasis in the HIV-infected patient: A case report. Exp Therapeutic Med. 2022;23(2):175. doi: 10.3892/etm.2021.11098

[18] Arbune M., Arbune M.M., Niculetet E., et al. Therapeutic challenges of psoriasis in the HIV-infected patient: A case report // Exp Therapeutic Med. 2022. Vol. 23, N 2. P. 175. doi: 10.3892/etm.2021.11098

[19] Plachouri KM, Georgiou S. Challenges in the treatment of psoriasis with biologics: Vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis. Int J Dermatol. 2019;58(9):1008–1013. doi: 10.1111/ijd.14436

[20] Plachouri K.M., Georgiou S. Challenges in the treatment of psoriasis with biologics: Vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis // Int J Dermatol. 2019. Vol. 58, N 9. P. 1008–1013. doi: 10.1111/ijd.14436

[21] Teh YC, Robinson S, Tan WC, et al. Psoriasis patients with human immunodeficiency virus infection: Data from the Malaysian psoriasis registry. Malaysian J Dermatol. 2021;46:1–10.

[22] Teh Y.C., Robinson S., Tan W.C., et al. Psoriasis patients with human immunodeficiency virus infection: Data from the Malaysian psoriasis registry // Malaysian J Dermatol. 2021. Vol. 46. P. 1–10.

[23] Myers B, Thibodeaux Q, Reddy V, et al. Biologic treatment of 4 HIV-positive patients: A case series and literature review. J Psoriasis Psoriatic Arthritis. 2021;6(1):19–26. doi: 10.1177/2475530320954279

[24] Myers B., Thibodeaux Q., Reddy V., et al. Biologic treatment of 4 HIV-positive patients: A case series and literature review // J Psoriasis Psoriatic Arthritis. 2021. Vol. 6, N 1. P. 19–26. doi: 10.1177/2475530320954279

[25] Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient. Focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53. doi: 10.1016/j.jaad.2018.06.056

[26] Kaushik S.B., Lebwohl M.G. Psoriasis: Which therapy for which patient. Focus on special populations and chronic infections // J Am Acad Dermatol. 2019. Vol. 80, N 1. P. 43–53. doi: 10.1016/j.jaad.2018.06.056

[27] Naovarat BS, Salazar G, Ishimori M, et al. Biological treatment usage in patients with HIV and rheumatic disease, 2003–2021: Long-term safety and follow-up. RMD Open. 2022;8(2):e002282. doi: 10.1136/rmdopen-2022-002282

[28] Naovarat B.S., Salazar G., Ishimori M., et al. Biological treatment usage in patients with HIV and rheumatic disease, 2003–2021: Long-term safety and follow-up // RMD Open. 2022. Vol. 8, N 2. P. e002282. doi: 10.1136/rmdopen-2022-002282

[29] Myers B, Thibodeaux Q, Reddy V, et al. Biologic treatment of 4 HIV-positive patients: A case series and literature review. J Psoriasis Psoriatic Arthritis. 2021;6(1):19–26. doi: 10.I177/2475530320954279

[30] Myers B., Thibodeaux Q., Reddy V., et al. Biologic treatment of 4 HIV-positive patients: A case series and literature review // J Psoriasis Psoriatic Arthritis. 2021. Vol. 6, N 1. P. 19–26. doi: 10.i177/2475530320954279

RIGHTS & PERMISSIONS

Eco-Vector